Is 2325.HK overvalued or undervalued?

2325.HK currently has a P/E ratio of 3.96. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Yunkang Group Limited stock?

Yunkang Group Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2325.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2325.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2325.HK to protect their purchasing power. Because 2325.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2325.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2325.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2325.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2325.HK

Yunkang Group Limited

HK$0.46+HK$0.01+1.10%

HKSE / HKD

Market cap

HK$269M

P/E

4.0

EPS (TTM)

HK$0.01

Dividend yield

0.00%

Beta

-0.80

1Y return

-65.15%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$267M2021

$544M2022

$126M2023

$97M2024

$86M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.59Low
Current ratio1.71
Cash ratio1.16
Net margin11.2%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2325.HK4.0
Healthcare sector median26.8
S&P 50022.0

Trades about 85% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.00
Price to book0.21
EPS (TTM)HK$0.01
Payout ratio0%
FCF yield47.31%

Range & risk

HK$0.44HK$2.10

Trading in the lower third of its 52-week band

Beta-0.80

Profile

What Yunkang Group Limited actually does

Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical institution alliances, which encompass assisting with the setup and enhancement of diagnostic centers, developing standard operating procedures for testing, delivering expert diagnostic consultations and staff training, sourcing necessary equipment, implementing smart Internet of Things technology, and providing logistics support. For diagnostic outsourcing, Yunkang Group conducts diverse tests, including pathology examinations; infectious disease diagnostics for conditions such as hepatitis B, tuberculosis, human papillomavirus, Epstein-Barr virus, rabies, and respiratory pathogens (via nucleic acid testing); genetic and reproductive health screenings; and routine diagnostic assessments for chronic ailments like kidney, blood, autoimmune, and endocrine metabolic diseases. Furthermore, the company caters to financial institutions and insurance firms by offering personalized diagnostic testing, medical report interpretation, and hospital referral services. Yunkang Group's capabilities also extend to information technology, medical logistics, procurement of medical equipment, healthcare technology development, and various project investments. These services are delivered through its network of independent clinical laboratories and integrated on-site diagnostic facilities.

CEO

Yong Zhang

Employees

1,064

Headquarters

Guangzhou, GD

Founded

2022-05-18

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2325.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2325.HK has a beta of -0.80, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Yunkang Group Limited